Paper29310082
Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.
Burmistrov V and 4 others. Bioorg Chem, 2018. Cited by 29 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability. Papers, record 29310082. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29310082
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adamantane | Major topic |
| Enzyme Inhibitors | Major topic |
| Epoxide Hydrolases | Major topic |
| Urea | Major topic |
| Animals | |
| Catalytic Domain | |
| Drug Stability | |
| Enzyme Assays | |
| Humans | |
| Mice | |
| Microsomes, Liver | |
| Molecular Docking Simulation | |
| Molecular Structure | |
| Rats |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P42 ES004699 | NIEHS NIH HHS | United States | P42ES004699 | PubMed and NIH | NIH RePORTER |
| R01 ES002710 | NIEHS NIH HHS | United States | R01ES002710 | PubMed and NIH | NIH RePORTER |
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,479,771 | Identification of potent inhibitors of the chicken soluble epoxide hydrolase. | Bioorg Med Chem Lett | 2015 | https://conductscience.org/library/papers/25479771 | PubMed |
| 2 | 15,963,942 | Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. | Anal Biochem | 2005 | https://conductscience.org/library/papers/15963942 | PubMed |
| 3 | 16,157,792 | An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. | Hypertension | 2005 | https://conductscience.org/library/papers/16157792 | PubMed |
| 4 | 24,685,540 | Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors. | Bioorg Med Chem Lett | 2014 | https://conductscience.org/library/papers/24685540 | PubMed |
| 5 | 11,090,543 | Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. | Circ Res | 2000 | https://conductscience.org/library/papers/11090543 | PubMed |
| 6 | 12,007,563 | Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. | Biochem Pharmacol | 2002 | https://conductscience.org/library/papers/12007563 | PubMed |
| 7 | 15,056,008 | Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. | J Med Chem | 2004 | https://conductscience.org/library/papers/15056008 | PubMed |
| 8 | 15,581,597 | Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. | Arch Biochem Biophys | 2005 | https://conductscience.org/library/papers/15581597 | PubMed |
| 9 | 20,664,072 | Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. | J Lipid Res | 2010 | https://conductscience.org/library/papers/20664072 | PubMed |
| 10 | 28,396,419 | Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28396419 | PubMed |
| 11 | 11,882,632 | Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. | Hypertension | 2002 | https://conductscience.org/library/papers/11882632 | PubMed |
| 12 | 18,248,310 | Eicosanoids and renal damage in cardiometabolic syndrome. | Expert Opin Drug Metab Toxicol | 2008 | https://conductscience.org/library/papers/18248310 | PubMed |
| 13 | 22,009,066 | EET signaling in cancer. | Cancer Metastasis Rev | 2011 | https://conductscience.org/library/papers/22009066 | PubMed |
| 14 | 4,584,115 | Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. | Xenobiotica | 1973 | https://conductscience.org/library/papers/4584115 | PubMed |
| 15 | 10,430,859 | Potent urea and carbamate inhibitors of soluble epoxide hydrolases. | Proc Natl Acad Sci U S A | 1999 | https://conductscience.org/library/papers/10430859 | PubMed |
| 16 | 8,307,189 | Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins. Implication for the potential catalytic mechanism of enzymatic epoxide hydrolysis. | FEBS Lett | 1994 | https://conductscience.org/library/papers/8307189 | PubMed |
| 17 | 23,045,145 | Measurement of soluble epoxide hydrolase (sEH) activity. | Curr Protoc Toxicol | 2007 | https://conductscience.org/library/papers/23045145 | PubMed |
| 18 | 15,887,969 | Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. | J Med Chem | 2005 | https://conductscience.org/library/papers/15887969 | PubMed |
| 19 | 17,616,115 | Orally bioavailable potent soluble epoxide hydrolase inhibitors. | J Med Chem | 2007 | https://conductscience.org/library/papers/17616115 | PubMed |
| 20 | 15,994,227 | Soluble epoxide hydrolase is a therapeutic target for acute inflammation. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15994227 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,761,581 | Human breath as a carbon dioxide source for organic synthesis. | RSC Adv | 2026 | https://conductscience.org/library/papers/42761581 | PubMed |
| 40,573,730 | Indole Alkaloids and Phenolic Amides from the Rhizomes of Cimicifuga heracleifolia and Their In Vitro Soluble Epoxide Hydrolase (sEH) Inhibitory Activity. | Plants (Basel) | 2025 | https://conductscience.org/library/papers/40573730 | PubMed |
| 38,203,510 | 1,3-Dichloroadamantyl-Containing Ureas as Potential Triple Inhibitors of Soluble Epoxide Hydrolase, p38 MAPK and c-Raf. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203510 | PubMed |
| 37,975,322 | Fluorine and chlorine substituted adamantyl-urea as molecular tools for inhibition of human soluble epoxide hydrolase with picomolar efficacy. | J Enzyme Inhib Med Chem | 2023 | https://conductscience.org/library/papers/37975322 | PubMed |
| 37,638,129 | Adamantyl-ureas with pyrazoles substituted by fluoroalkanes as soluble epoxide hydrolase inhibitors. | J Fluor Chem | 2023 | https://conductscience.org/library/papers/37638129 | PubMed |
| 37,601,415 | Ureas derived from camphor and fenchone reveal enantiomeric preference of human soluble epoxide hydrolase. | Results Chem | 2022 | https://conductscience.org/library/papers/37601415 | PubMed |
| 37,110,811 | Synthesis and Properties of 1,3-Disubstituted Ureas Containing (Adamantan-1-yl)(phenyl)methyl Fragment Based on One-Pot Direct Adamantane Moiety Inclusion. | Molecules | 2023 | https://conductscience.org/library/papers/37110811 | PubMed |
| 36,142,611 | Anti-Inflammatory Activity of Soluble Epoxide Hydrolase Inhibitors Based on Selenoureas Bearing an Adamantane Moiety. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36142611 | PubMed |
| 35,271,276 | Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. | J Med Chem | 2022 | https://conductscience.org/library/papers/35271276 | PubMed |
| 33,945,278 | From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. | J Med Chem | 2021 | https://conductscience.org/library/papers/33945278 | PubMed |
| 33,575,076 | Adamantane-linked isothiourea derivatives suppress the growth of experimental hepatocellular carcinoma via inhibition of TLR4-MyD88-NF-κB signaling. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/33575076 | PubMed |
| 33,369,424 | Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products. | J Med Chem | 2021 | https://conductscience.org/library/papers/33369424 | PubMed |
| 33,101,030 | Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33101030 | PubMed |
| 33,007,552 | Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain. | Bioorg Med Chem | 2020 | https://conductscience.org/library/papers/33007552 | PubMed |
| 32,824,969 | Polycarbonate/Sulfonamide Composites with Ultralow Contents of Halogen-Free Flame Retardant and Desirable Compatibility. | Materials (Basel) | 2020 | https://conductscience.org/library/papers/32824969 | PubMed |
| 32,736,212 | Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors. | Bioorg Med Chem Lett | 2020 | https://conductscience.org/library/papers/32736212 | PubMed |
| 32,132,741 | Fluoroaromatic fragments on 1,3-disubstituted ureas enhance soluble epoxide hydrolase inhibition. | J Fluor Chem | 2019 | https://conductscience.org/library/papers/32132741 | PubMed |
| 32,032,849 | Protostane-type triterpenoids as natural soluble epoxide hydrolase inhibitors: Inhibition potentials and molecular dynamics. | Bioorg Chem | 2020 | https://conductscience.org/library/papers/32032849 | PubMed |
| 31,870,649 | Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility. | Bioorg Med Chem Lett | 2020 | https://conductscience.org/library/papers/31870649 | PubMed |
| 31,488,357 | Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. | Bioorg Med Chem | 2019 | https://conductscience.org/library/papers/31488357 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EPHX2 | 2,053 | PubTator's text mining | https://conductscience.org/library/genes/2053 | NCBI Gene |
| SLTM | 79,811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29310082
GET https://conductscience.org/api/papers/v1/29310082/references?page=2